These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 21839812)

  • 1. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
    Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
    Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
    Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
    Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
    Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
    Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
    Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
    Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
    Frau L; Borsini F; Wardas J; Khairnar AS; Schintu N; Morelli M
    Synapse; 2011 Mar; 65(3):181-8. PubMed ID: 20665698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Luo Y; Yin W; Signore AP; Zhang F; Hong Z; Wang S; Graham SH; Chen J
    J Neurochem; 2006 Apr; 97(2):435-48. PubMed ID: 16539667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
    Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
    J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
    Kim S; Moon M; Park S
    J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms.
    Thal SC; Heinemann M; Luh C; Pieter D; Werner C; Engelhard K
    J Neurotrauma; 2011 Jun; 28(6):983-93. PubMed ID: 21501066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
    J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor.
    García C; Gómez-Cañas M; Burgaz S; Palomares B; Gómez-Gálvez Y; Palomo-Garo C; Campo S; Ferrer-Hernández J; Pavicic C; Navarrete C; Luz Bellido M; García-Arencibia M; Ruth Pazos M; Muñoz E; Fernández-Ruiz J
    J Neuroinflammation; 2018 Jan; 15(1):19. PubMed ID: 29338785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease models.
    Lecca D; Janda E; Mulas G; Diana A; Martino C; Angius F; Spolitu S; Casu MA; Simbula G; Boi L; Batetta B; Spiga S; Carta AR
    Br J Pharmacol; 2018 Aug; 175(16):3298-3314. PubMed ID: 29570770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.
    Lecca D; Nevin DK; Mulas G; Casu MA; Diana A; Rossi D; Sacchetti G; Fayne D; Carta AR
    Neuroscience; 2015 Aug; 302():23-35. PubMed ID: 25907448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Goldberg NR; Haack AK; Lim NS; Janson OK; Meshul CK
    Neuroscience; 2011 Apr; 180():256-71. PubMed ID: 21335067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.
    Sriram K; Matheson JM; Benkovic SA; Miller DB; Luster MI; O'Callaghan JP
    FASEB J; 2006 Apr; 20(6):670-82. PubMed ID: 16581975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
    Schmidt N; Ferger B
    Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
    Laloux C; Petrault M; Lecointe C; Devos D; Bordet R
    Pharmacol Res; 2012 May; 65(5):514-22. PubMed ID: 22391246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
    Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
    Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.